These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 14961027)

  • 21. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
    Mozziconacci MJ; Caillères S; Maurice C; Vey N; Sainty D; Blaise D; Lafage-Pochitaloff M
    Leukemia; 2003 Sep; 17(9):1901-2. PubMed ID: 12970792
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 23. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.
    Kiguchi T; Tauchi T; Ito Y; Miyazawa K; Kimura Y; Ohyashiki K
    Leuk Res; 2009 Mar; 33(3):506-8. PubMed ID: 18533259
    [No Abstract]   [Full Text] [Related]  

  • 24. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
    Chee YL; Vickers MA; Stevenson D; Holyoake TL; Culligan DJ
    Leukemia; 2003 Mar; 17(3):634-5. PubMed ID: 12646955
    [No Abstract]   [Full Text] [Related]  

  • 25. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
    Némati F; Mathiot C; Grandjean I; Lantz O; Bordier V; Dewulf S; Ekue R; Di Santo JP; Poupon MF; Decaudin D
    Anticancer Drugs; 2007 Oct; 18(9):1029-37. PubMed ID: 17704653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imatinib-induced erythroderma.
    Mathew T; Chandrashekar L; Pulimood S; Srivastava A
    Australas J Dermatol; 2007 Aug; 48(3):193-4. PubMed ID: 17680975
    [No Abstract]   [Full Text] [Related]  

  • 27. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
    Wassmann B; Klein SA; Scheuring U; Pfeifer H; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
    Bone Marrow Transplant; 2001 Oct; 28(7):721-4. PubMed ID: 11704799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C; Saikia T; Bakshi A; Amare-Kadam P; Baisane C; Parikh P
    J Assoc Physicians India; 2005 Apr; 53():291-5. PubMed ID: 15987013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
    Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
    Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia].
    Turkina AG; Khoroshko ND; Druzhkova GA; Zingerman BV; Zakharova ES; Chelysheva EIu; Vinogradova OIu; Domracheva EV; Zakharova AV; Kovaleva LG
    Ter Arkh; 2003; 75(8):62-7. PubMed ID: 14520855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
    Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
    Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
    [No Abstract]   [Full Text] [Related]  

  • 33. Imatinib mesylate.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
    Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
    Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The role of imatinib in the treatment of acute lymphoid leukemias].
    Poros A; Lovas N
    Orv Hetil; 2005 May; 146(18 Suppl 1):905-10. PubMed ID: 15921303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia.
    Quintas-Cardama A; Kantarjian H; O'Brien S; Garcia-Manero G; Rios MB; Talpaz M; Cortes J
    Cancer; 2004 Jun; 100(12):2592-7. PubMed ID: 15197801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shooting the messenger (RNA) in B-cell lymphoma.
    Yeomans A; Packham G
    Blood; 2016 Feb; 127(7):794-6. PubMed ID: 26893394
    [No Abstract]   [Full Text] [Related]  

  • 39. Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.
    Thiant S; Moutuou MM; Laflamme P; Sidi Boumedine R; Leboeuf DM; Busque L; Roy J; Guimond M
    Blood Cancer J; 2017 Apr; 7(4):e551. PubMed ID: 28387753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.
    Chand M; Thakuri M; Keung YK
    Leukemia; 2004 Apr; 18(4):886-7; author reply 887-8. PubMed ID: 14961027
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.